Actively Recruiting
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Led by M.D. Anderson Cancer Center · Updated on 2026-03-04
50
Participants Needed
1
Research Sites
235 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
CONDITIONS
Official Title
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with advanced clear cell renal cell carcinoma, mesothelioma, or osteosarcoma expressing CD70 as measured by tumor testing
- At least 16 and no older than 80 years of age
- Weight at least 40 kg
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate kidney, liver, heart, lung, blood, and coagulation function as defined by study criteria
- At least 2 weeks since last chemotherapy, targeted therapy, or tyrosine kinase inhibitor before lymphodepleting chemotherapy
- At least 3 months since any previous cell therapy for cancer
- Measurable or evaluable disease per RECIST v1.1 criteria depending on cancer type
- Able to provide informed consent (and pediatric assent if applicable)
- Effective birth control for patients able to have children during and for 3 months after study therapy
- Negative pregnancy test for females of childbearing potential
- Signed consent for long-term follow-up
You will not qualify if you...
- Ongoing significant toxicity from prior cancer treatments above Grade 1
- Active infections requiring IV antibiotics or not responding to treatment
- Known active hepatitis B or C infection
- Detectable HIV viral load or antiretroviral therapy incompatible with study drugs
- Active neurological disorders
- Autoimmune disease within 12 months (except controlled psoriasis or thyroid disease)
- Amyloidosis or POEMS syndrome
- Symptomatic or uncontrolled central nervous system involvement
- Other recent malignancies within 2 years except certain treated cancers
- Serious heart conditions such as recent heart attack, unstable angina, severe aortic stenosis, or uncontrolled arrhythmias
- Major surgery within 4 weeks before study treatment
- Use of other investigational or anticancer agents
- Prior anti-CD70 therapy
- Systemic steroids above low doses or immunosuppressive therapy
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
David Hong, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here